November 2008 Volume 22 Number 11, pp 1975 - 2135
-------------------------------------------------------------------
Featured Immunology & Cell Biology Articles
FREE for a Limited Time
You are invited to take advantage of some of the best articles from
Immunology & Cell Biology free of charge. Highlighting the latest
within its field, this special offer is available for only a few
months so act now!
Take advantage of this limited time special by visiting
http://links.ealert.nature.com/ctt?kn=78&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
----------------------
SPOTLIGHT EDITORIAL
----------------------
BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative
disorders: some common and contrasting features
N C P Cross, G Q Daley, A R Green, T P Hughes, C Jamieson, P Manley, T
Mughal, D Perrotti, J Radich, R Skoda, S Soverini, W Vainchenker, S
Verstovsek, J-L Villeval and J M Goldman
http://links.ealert.nature.com/ctt?kn=97&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
----------------------
SPOTLIGHT REVIEWS
----------------------
Interferon-[alpha] therapy in bcr-abl-negative myeloproliferative
neoplasms
J-J Kiladjian, C Chomienne and P Fenaux
Abstract:
http://links.ealert.nature.com/ctt?kn=114&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Article:
http://links.ealert.nature.com/ctt?kn=57&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Five years since the discovery of FIP1L1-PDGFRA: what we have learned
about the fusion and other molecularly defined eosinophilias
J Gotlib and J Cools
Abstract:
http://links.ealert.nature.com/ctt?kn=22&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Article:
http://links.ealert.nature.com/ctt?kn=61&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Miscreant myeloproliferative disorder stem cells
C H M Jamieson, C F Barroga and W P Vainchenker
Abstract:
http://links.ealert.nature.com/ctt?kn=71&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Article:
http://links.ealert.nature.com/ctt?kn=9&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Thrombosis in myeloproliferative disorders: pathogenetic facts and
speculation
R Landolfi, L Di Gennaro and A Falanga
Abstract:
http://links.ealert.nature.com/ctt?kn=66&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Article:
http://links.ealert.nature.com/ctt?kn=14&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
----------------------
REVIEW
----------------------
Investigating human leukemogenesis: from cell lines to in vivo models
of human leukemia
J A Kennedy and F Barabe
Abstract:
http://links.ealert.nature.com/ctt?kn=80&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Article:
http://links.ealert.nature.com/ctt?kn=40&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
----------------------
ORIGINAL ARTICLES
----------------------
HOX expression patterns identify a common signature for favorable AML
M Andreeff, V Ruvolo, S Gadgil, C Zeng, K Coombes, W Chen, S Kornblau,
A E Baron and H A Drabkin
Abstract:
http://links.ealert.nature.com/ctt?kn=11&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Article:
http://links.ealert.nature.com/ctt?kn=36&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Rituximab in combination with high-dose methylprednisolone for the
treatment of fludarabine refractory high-risk chronic lymphocytic
leukemia
J E Castro, J D Sandoval-Sus, J Bole, L Rassenti and T J Kipps
Abstract:
http://links.ealert.nature.com/ctt?kn=3&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Article:
http://links.ealert.nature.com/ctt?kn=23&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Secretion of angiogenic proteins by human multipotent mesenchymal
stromal cells and their clinical potential in the treatment of
avascular osteonecrosis
I Muller, M Vaegler, C Holzwarth, N Tzaribatchev, S M Pfister, B
Schutt, P Reize, J Greil, R Handgretinger and M Rudert
Abstract:
http://links.ealert.nature.com/ctt?kn=35&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Article:
http://links.ealert.nature.com/ctt?kn=82&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Impact of comorbidity indexes on non-relapse mortality
A Xhaard, R Porcher, J W Chien, R P de Latour, M Robin, P Ribaud, V
Rocha, A Devergie, C Ferry, P J Martin and G Socie
Abstract:
http://links.ealert.nature.com/ctt?kn=27&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Article:
http://links.ealert.nature.com/ctt?kn=12&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Ex vivo priming of CD4 T cells converts immunological tolerance into
effective antitumor immunity in a murine model of acute lymphoblastic
leukemia
A N Hegazy and C Klein
Abstract:
http://links.ealert.nature.com/ctt?kn=74&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Article:
http://links.ealert.nature.com/ctt?kn=123&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Involvement of p53 and Raf//MEK//ERK pathways in hematopoietic drug
resistance
J A McCubrey, S L Abrams, G Ligresti, N Misaghian, E W T Wong, L S
Steelman, J Basecke, J Troppmair, M Libra, F Nicoletti, S Molton, M
McMahon, C Evangelisti and A M Martelli
Abstract:
http://links.ealert.nature.com/ctt?kn=98&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Article:
http://links.ealert.nature.com/ctt?kn=91&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in
lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing
G1 cell cycle arrest and apoptosis
L Gu, J Gao, Q Li, Y P Zhu, C S Jia, R Y Fu, Y Chen, Q K Liao and Z Ma
Abstract:
http://links.ealert.nature.com/ctt?kn=59&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Article:
http://links.ealert.nature.com/ctt?kn=39&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle
cell lymphoma has minimal effects on cell survival and reveals a
regulatory circuit with cyclin D2
M Klier, N Anastasov, A Hermann, T Meindl, D Angermeier, M Raffeld, F
Fend and L Quintanilla-Martinez
Abstract:
http://links.ealert.nature.com/ctt?kn=44&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Article:
http://links.ealert.nature.com/ctt?kn=111&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
----------------------
LETTERS TO THE EDITOR
----------------------
STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression
in primary mediastinal B-Cell lymphoma
O Ritz, C Guiter, K Dorsch, I Dusanter-Fourt, S Wegener, H Jouault, P
Gaulard, F Castellano, P Moller and K Leroy
http://links.ealert.nature.com/ctt?kn=118&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Amonafide L-malate is not a substrate for multidrug resistance
proteins in secondary acute myeloid leukemia
M Burcu, K L O'Loughlin, L A Ford and M R Baer
http://links.ealert.nature.com/ctt?kn=93&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
In-vivo detectable antibodies directed against the oncofetal
antigen/immature laminin receptor can recognize and control myeloma
cells-clinical implications
S Siegel, B Friedrichs, A-K Budde, A Barsoum, J Coggin, M Tiemann, D
Kabelitz and M Zeis
http://links.ealert.nature.com/ctt?kn=105&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
The WHO 2008 classification of Ph-myeloproliferative disorders:
statement of the Czech MPD Working Group
J Schwarz, M Penka, K Indrak, D Pospisilova, R Pytlik, P Dulicek, M
Doubek, L Kren and V Campr
http://links.ealert.nature.com/ctt?kn=49&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Genomic typing for patient-specific human leukocyte antigen-alleles is
an efficient tool for relapse detection of high-risk hematopoietic
malignancies after stem cell transplantation from alternative donors
B Mazzi, T D Clerici, M Zanussi, M T Lupo Stanghellini, L Vago, E
Sironi, J Peccatori, M Bernardi, P Carrera, A Palini, S Rossini, C
Bordignon, C Bonini, M Ferrari, F Ciceri and K Fleischhauer
http://links.ealert.nature.com/ctt?kn=43&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
The most frequent t(14;19)(q32;q13)-positive B-cell malignancy
corresponds to an aggressive subgroup of atypical chronic lymphocytic
leukemia
E Chapiro, I Radford-Weiss, C Bastard, I Luquet, C Lefebvre, E
Callet-Bauchu, D Leroux, P Talmant, M-J Mozziconacci, F Mugneret, S
Struski, S Raynaud, J Andrieux, C Barin, M Jotterand, H Mossafa, S
Ramond, C Terre, E Lippert, F Berger, P Felman, H Merle-Beral, O A
Bernard, F Davi, R Berger and F Nguyen-Khac
http://links.ealert.nature.com/ctt?kn=1&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Gynecomastia in a male after dasatinib treatment for chronic myeloid
leukemia
G Caocci, S Atzeni, N Orru, L Azzena, L Martorana, R Littera, A Ledda
and G La Nasa
http://links.ealert.nature.com/ctt?kn=73&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Association of KIR2DS4 and its variant KIR1D with leukemia
S Giebel, I Nowak, J Wojnar, M Krawczyk-Kulis, J Holowiecki, S
Kyrcz-Krzemien and P Kusnierczyk
http://links.ealert.nature.com/ctt?kn=109&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Reply to: Association of KIR2DS4 and its variant KIR1D with leukemia
S Verheyden and C Demanet
http://links.ealert.nature.com/ctt?kn=10&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Reply to Verheyden and Demanet
S Giebel, I Nowak, E Majorczyk and P Kusnierczyk
http://links.ealert.nature.com/ctt?kn=28&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs)
progenitors to fludarabine suggests impaired bone marrow niche and HP
mobilization
M G Berger, J Berger, C Richard, S Jeanpierre, F E Nicolini, O
Tournilhac, M Michallet and V M Satta
http://links.ealert.nature.com/ctt?kn=99&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
----------------------
CORRIGENDUM
----------------------
Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs)
progenitors to fludarabine suggests impaired bone marrow niche and HP
mobilization
M G Berger, J Berger, C Richard, S Jeanpierre, F E Nicolini, O
Tournilhac, M Michallet and V Maguer-Satta
http://links.ealert.nature.com/ctt?kn=62&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
----------------------------------------------------------------------------
Bone Marrow Transplantation delivers only the finest content in
the following areas:
Hematopoietic stem cell transplantation, stem cell biology,
transplantation immunology, kinetics and cytokine control, HLA and
matching techniques, translational research, clinical results.
Published 24 times a year, Bone Marrow Transplantation is an excellent
source for the latest findings in the field. Visit
http://links.ealert.nature.com/ctt?kn=8&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
for free featured articles and more!
======================================================================
You have been sent this Table of Contents Alert because you have opted in to receive it.
You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=18&m=30599108&r=MTI0MDgxNDQ5OQS2&b=2&j=NDMwMTg5NTkS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and
Wales under company number 785998 and whose registered office is located
at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
(c) Copyright 2008 Nature Publishing Group
======================================================================
